Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease melanoma, malignant
Symptom C0220650|brain metastasis
Sentences 11
PubMedID- 26217117 There are recent data using the anti-ctla-4 antibody ipilimumab at a dose of 10 mg/kg every 3 weeks for four cycles in melanoma patients with brain metastasis, with a response rate of 16% in asymptomatic and 5% in symptomatic patients.
PubMedID- 25695690 The efficacy of this agent in kit-altered melanoma with brain metastasis is limited.
PubMedID- 24795353 Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates.
PubMedID- 26421283 Temozolomide is an alkylating agent used in malignant brain tumors and in malignant melanoma (with brain metastasis).
PubMedID- 20216240 Anecdotal cases of partial or complete responses have been reported after ipilimumab therapy for stage iv melanoma with brain metastasis treated earlier by surgery or radiosurgery.
PubMedID- 23392133 Angiotropism in primary cutaneous melanoma with brain metastasis: a study of 20 cases.
PubMedID- 23082737 The high rate of brain metastasis in patients with advanced melanoma has been a clinical challenge for oncologists.
PubMedID- 22577532 brain metastasis is common in patients with melanoma and represents a significant cause of morbidity and mortality.
PubMedID- 23824275 Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
PubMedID- 22488042 The current analysis was conducted with samples from patients treated at a single institution, which pursues aggressive surgical and multimodality treatment of metastatic melanoma, including in patients with brain metastasis that could bias these results in a favorable manner.
PubMedID- 24265631 Notably, the finding that tcr gene-engineered t cells were able to traffic to the central nervous system and cause complete responses of brain metastasis in patients with melanoma was not only encouraging but also underscored the strength of t cell therapy toward metastasized and poorly accessible tumors (7).

Page: 1